Status:
COMPLETED
FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms
Lead Sponsor:
Fervent Pharmaceuticals
Collaborating Sponsors:
ICON plc
Conditions:
Vasomotor Symptoms
Menopause
Eligibility:
FEMALE
46+ years
Phase:
PHASE2
Brief Summary
This Phase II proof of concept study is designed to assess the safety and efficacy of FP-101 (60mg b.i.d.), an extended-release oral tablet product, compared to a matching placebo in the treatment of ...
Detailed Description
This randomized, double-blind, parallel-group, placebo-controlled, clinical trial is designed to compare patient-reported changes in Vasomotor Symptoms (VMS) for FP-101 vs. placebo in peri- and post-m...
Eligibility Criteria
Inclusion
- Peri- and Post-Menopausal female subjects (\>45 yrs) experiencing a min of 7-8 moderate to severe hot flashes per day
- Able/willing to provide informed consent.
- Able/willing to complete all study procedures and visits.
- Able/willing to not use any over-the-counter (OTC) cough \& cold medications that contain the IMP active during the study.
Exclusion
- Subject exhibits positive home pregnancy test at screening or any time during study
- Subject currently taking any form of Hormone Therapy (HT), including local estrogen therapies
- Subject currently taking tamoxifen, other selective estrogen receptor modulators, or other hormone deprivation therapy.
- Subject with history of serotonergic syndrome
- Subject is currently taking monoamine oxidase inhibitors (MAOIs) (or for 2 weeks after stopping the MAOI drug), antidepressants, thioridazine, pimozide, cannabidiol, opioids, antipsychotic agents, antiretroviral agents, quinidine, quinine, or other medications for VMS such as Brisdelle® (paroxetine mesylate), clonidine and gabapentin.
- Subject is currently taking a dietary/herbal supplement(s) to manage VMS, such as soy isoflavones or black cohosh.
- Subject has uncontrolled diabetes, a history of hypertension \& is not on a stable dose of antihypertensive medications for at least 30 days prior to screening.
- Subject has clinically unstable cardiac disease, including atrial fibrillation, symptomatic brady- or tachy-arrhythmias, congestive heart failure (NYHA class II, III, and IV), or symptomatic atherosclerotic cardiovascular disease (coronary artery disease, carotid artery disease or peripheral artery disease) or history of myocardial infarction or stroke within 2 years of enrolment in the study.
- Subject reports medical history suggestive of impaired liver/kidney function or, in the PI's opinion, exhibits liver/kidney function impairment to the extent that the subject should not participate in the study.
- Subject has biliary tract disease, adrenal cortical insufficiency, or any other medical condition that, in the PI's opinion (and after discussion with the medical monitor), is considered inadequately treated and precludes entry into the study.
- Subject has thyroid disease, unless subject is clinically stable with normal thyroid indices and is on maintenance thyroid medication (e.g., levothyroxine or liothyronine) for ≥6 months prior to screening.
- Subject has a history of, or is currently presenting with, substance use disorder as defined by the 5th Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM). Subject has a history of psychiatric disorders, including a lifetime history of major depressive disorder, bipolar disorder, panic disorder, generalized anxiety, psychotic disorders, suicidality or suicidal ideation, or post-traumatic stress disorder.
- Subject is currently participating in another clinical trial
- Subjects who were determined to be placebo responders or non-compliant during the 1-week run-in period.
Key Trial Info
Start Date :
March 24 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2023
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT05312567
Start Date
March 24 2021
End Date
July 31 2023
Last Update
October 26 2023
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Torrance Clinical Research Institute
Lomita, California, United States, 90717
2
Long Beach Clinical Trial Services
Long Beach, California, United States, 90806
3
Provideré Research Inc.
West Covina, California, United States, 91790
4
Inpatient Research Clinic
Hialeah, Florida, United States, 33013